NTHI
$8.86
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies.
Intraday
Recent News
Insider Buys Additional US$185k In NeOnc Technologies Holdings Stock
Investors who take an interest in NeOnc Technologies Holdings, Inc. ( NASDAQ:NTHI ) should definitely note that the...
With 61% ownership, NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) insiders have a lot riding on the company's future
Key Insights Insiders appear to have a vested interest in NeOnc Technologies Holdings' growth, as seen by their...
AI and biotech take on brain cancer
You can catch Trader Talk on Apple Podcasts, Spotify, YouTube, or wherever you get your podcasts. When a biotech startup lands in a major index just months after its IPO, investors take notice. In this episode of Trader Talk, Kenny Polcari speaks with Amir Heshmatpour, executive chairman and president of NeOnc Technologies (NTHI), about how the company defied a tough market to go public, secure a $50 million partnership in the Middle East, and join the Russell Microcap Index. Heshmatpour explains NeOnc’s focus on intranasal drug delivery for brain cancer, the significance of its partnership with USC’s medical school, and how global clinical trials are expanding the company’s reach. The conversation also includes how AI and quantum computing could transform the biotech industry. It’s a rare behind-the-scenes look at how a small-cap biotech is executing on a global stage. Watch more episodes of Trader Talk here. Trader Talk with Kenny Polcari on Yahoo Finance delivers expert analysis and actionable insights, empowering you to navigate market volatility and secure your financial future. This post was written by Langston Sessoms.
NeOnc Technologies Holdings Insiders Lose Out As Stock Sinks To US$3.72
The recent 22% drop in NeOnc Technologies Holdings, Inc.'s ( NASDAQ:NTHI ) stock could come as a blow to insiders who...